Gottlieb, A.; Blauvelt, A.; Tha?i, D.; Poulin, Y.; Brock, F.; Arendt, C.; Boehnlein, M.; Reich, K. Reductions in Absolute PASI Over 144 Weeks of Treatment With Certolizumab Pegol in Patients With Plaque Psoriasis: Pooled Analysis from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2). J of Skin 2020, 4, s84.